Nucleic acid expression platform with increased expression efficiency
The nucleic acid expression platform with translation control elements enhances the efficiency of expressing eukaryotic proteins by using human-derived regulatory sequences, addressing the inefficiencies in existing systems and improving gene expression for vaccines and therapy.
Patent Information
- Application Number
- JP2024557871
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-13
- Filing Date
- 2022-12-09
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-12-09
AI Technical Summary
Existing nucleic acid expression systems lack efficiency in expressing eukaryotic proteins, particularly for applications in gene therapy agents and nucleic acid vaccines, necessitating improved systems for enhanced expression efficiency.
A nucleic acid expression platform incorporating a translation control element with upstream and downstream translational regulatory elements, including sequences derived from human proteins such as troponin T1, albumin, ferritin light chain, and chemokine ligand, to enhance the expression of target genes.
The platform stabilizes expressed transcripts and significantly improves the efficiency of expressing target genes, including reporter genes, infectious antigens, and therapeutic peptides, making it suitable for vaccines and gene therapy agents.
Smart Images

Figure 2024545367000001_ABST
Abstract
Description
[Technical field]
[0001] This patent application relates to the results of the "Development of a new mRNA vaccine platform" project (supervising agency: The Catholic University of Korea Industry-Academia Collaboration Foundation; project number: 1711158916) as part of the "New and Variant Infectious Disease Response Platform Core Technology Development Project" by the Ministry of Science, ICT and Communications of the Korean government, and the "Research on Toxicity Assessment Technology Development for mRNA Vaccines, etc. (1)" project (supervising agency: The Catholic University of Korea Industry-Academia Collaboration Foundation; project number: 1475013322) as part of the "Innovative Technology Support Research Project for Infectious Disease Response" by the Ministry of Food and Drug Safety of the Korean government.
[0002] The present disclosure relates to a nucleic acid expression platform, and more particularly to a nucleic acid expression platform or a nucleic acid expression system, such as a nucleic acid molecule having increased expression efficiency and a recombinant expression vector comprising the same. [Background technology]
[0003] Since the advent of recombinant gene technology in the 1970s, expression systems capable of expressing a gene of interest (GOI) have been known. One such expression system is the cell-based expression system, which uses expression systems from microorganisms or eukaryotes, while cell-free expression systems generally use purified RNA polymerase, ribosomes, tRNA, and ribonucleotides.
[0004] In particular, proteins derived from eukaryotic cells undergo post-translational modifications such as phosphorylation, methylation, and glycosylation after expression, but microorganisms do not have such post-translational modification mechanisms, so when expressing eukaryotic cell-derived proteins, a eukaryotic cell expression system must be used.
[0005] Eukaryotic cell-induced expression systems can be used for gene therapy agents, nucleic acid vaccines, etc. In the case of gene therapy agents, a target gene consisting of an open reading frame (ORF) encoding a peptide or protein capable of treating various diseases is inserted into the expression system. In the case of nucleic acid vaccines, a target gene consisting of an open reading frame encoding a peptide or protein capable of being expressed as an antigen is inserted into the expression system. However, there is a constant demand in related technical fields for a nucleic acid expression system capable of improving the expression efficiency of a target gene. Summary of the Invention [Problem to be solved by the invention]
[0006] An object of the present disclosure is to provide a nucleic acid expression platform or a nucleic acid expression system that can improve the expression efficiency of a target gene. [Means for solving the problem]
[0007] According to one aspect, a nucleic acid molecule is disclosed that includes a translational regulatory element and a coding region operably linked to the translational regulatory element, the translational regulatory element including an upstream translational regulatory element located upstream of the coding region and a downstream translational regulatory element located downstream of the coding region, the downstream translational regulatory element including a plurality of downstream translational regulatory elements.
[0008] In exemplary embodiments, the downstream translational regulatory element may include a first downstream translational regulatory element and a second downstream translational regulatory element located downstream of the coding region.
[0009] As an example, the multiple downstream translational regulatory elements (e.g., the first downstream translational regulatory element and the second downstream translational regulatory element) may each include a translational regulatory element or a transcript sequence derived from any one of genes selected from the group consisting of human troponin T1, slow backbone type (human TNNT1), human albumin, human ferritin light chain (human FTL), human CC motif chemokine ligand (human CCL19), human vascular-associated migratory cell protein (human AAMP), human ribosomal protein S27 (human RPS27) and human defensin alpha 5 (human DEFA5).
[0010] The multiple downstream translational regulatory elements (e.g., the first downstream translational regulatory element and the second downstream translational regulatory element) may each independently comprise a translational regulatory element selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, or a transcript sequence thereof.
[0011] In an exemplary embodiment, the first downstream translational regulatory element comprises a translational regulatory element derived from the human TNNT1 or a transcript sequence thereof, and the second downstream translational regulatory element may comprise a translational regulatory element derived from any one selected from the group consisting of the human albumin, the human FTL, the human CCL19, the human AAMP, the human RPS27, and the human DEFA5 or a transcript sequence thereof.
[0012] In other exemplary embodiments, the first downstream translational regulatory element may comprise a translational regulatory element derived from human albumin or a transcript sequence thereof, and the second downstream translational regulatory element may comprise a translational regulatory element derived from human DEFA5 or a transcript sequence thereof.
[0013] In yet another exemplary embodiment, the first downstream translational regulatory element may comprise a translational regulatory element derived from the human FTL or a transcript sequence thereof, and the second downstream translational regulatory element may comprise a translational regulatory element derived from any one selected from the group consisting of the human TNNT1, the human FTL, the human RPS27 and the human DEFA5 or a transcript sequence thereof.
[0014] In yet another exemplary embodiment, the first downstream translation regulatory element comprises a translation regulatory element derived from the human CCL19 or a transcript sequence thereof, and the second downstream translation regulatory element may comprise a translation regulatory element derived from any one selected from the group consisting of the human TNNT1, the human FTL, the human CCL19, the human RPS27, and the human DEFA5 or a transcript sequence thereof.
[0015] In yet another exemplary embodiment, the first downstream translational regulatory element may include a translational regulatory element derived from the human AAMP or a transcript sequence thereof, and the second downstream translational regulatory element may include a translational regulatory element derived from any one selected from the group consisting of the human albumin, the human FTL, the human RPS27 and the human DEFA5 or a transcript sequence thereof.
[0016] In yet another exemplary embodiment, the first downstream translation regulatory element may comprise a translation regulatory element derived from human RPS27 or a transcript sequence thereof, and the second downstream translation regulatory element may comprise a translation regulatory element derived from any one selected from the group consisting of human TNNT1, human albumin, human FTL, human CCL19, human AAMP, human RPS27 and human DEFA5 or a transcript sequence thereof.
[0017] In yet another exemplary embodiment, the first downstream translation regulatory element may comprise a translation regulatory element derived from human DEFA5 or a transcript sequence thereof, and the second downstream translation regulatory element may comprise a translation regulatory element derived from any one selected from the group consisting of human TNNT1, human albumin, human FTL, human CCL19, human AAMP and human RPS27, or a transcript sequence thereof.
[0018] In yet other exemplary embodiments, the downstream translational regulatory element may further comprise a third downstream translational regulatory element located downstream of the second downstream translational regulatory element.
[0019] The third downstream translational regulatory element may include a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human troponin T1, slow backbone type (TNNT1), human albumin, human ferritin light chain (FTL), human CC motif chemokine ligand (CCL19), human vascular-associated migratory cell protein (AAMP), human ribosomal protein S27 (RPS27) and human defensin alpha 5 (DEFA5).
[0020] For example, the first downstream translation regulatory element may comprise a translation regulatory element derived from human TNNT1 or a transcript sequence thereof, the second downstream translation regulatory element may comprise a translation regulatory element derived from human DEFA5 or a transcript sequence thereof, and the third downstream translation regulatory element may comprise a translation regulatory element derived from human FTL or human RPS27 or a transcript sequence thereof.
[0021] In other exemplary embodiments, the first downstream translation regulatory element may comprise a translation regulatory element derived from human albumin or a transcript sequence thereof, the second downstream translation regulatory element may comprise a translation regulatory element derived from human DEFA5 or a transcript sequence thereof, and the third downstream translation regulatory element may comprise a translation regulatory element derived from human RPS27 or a transcript sequence thereof.
[0022] In yet other exemplary embodiments, the first downstream translation regulatory element may comprise a translation regulatory element derived from human RPS27 or a transcript sequence thereof, the second downstream translation regulatory element may comprise a translation regulatory element derived from human FTL or a transcript sequence thereof, and the third downstream translation regulatory element may comprise a translation regulatory element derived from any one selected from the group consisting of human CCL19, human RPS27, and human DEFA5 or a transcript sequence thereof.
[0023] In yet other exemplary embodiments, the first downstream translation regulatory element may comprise a transcriptional translation regulatory element derived from human DEFA5 or a transcript sequence thereof, the second downstream translation regulatory element may comprise a translational regulatory element derived from human TNNT1 or a transcript sequence thereof, and the third downstream translation regulatory element may comprise a translational regulatory element derived from human FTL or a transcript sequence thereof.
[0024] The upstream translational regulatory element may include a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human troponin T1, slow backbone type (human TNNT1), human albumin, human ferritin light chain (human FTL), human CC motif chemokine ligand (human CCL19), human vascular-associated migratory cell protein (human AAMP), human ribosomal protein S27 (human RPS27) and human defensin alpha 5 (human DEFA5).
[0025] As an example, the upstream translational regulatory element may comprise a translational regulatory element selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, or a transcript sequence thereof.
[0026] The nucleic acid molecule may be RNA.
[0027] The nucleic acid molecule may further comprise a transcriptional regulatory element operably linked to the coding region.
[0028] In alternative embodiments, the nucleic acid molecule may further comprise a polyadenylation signal sequence or a polyadenosine sequence located downstream of the downstream translational regulatory sequence.
[0029] In exemplary embodiments, the coding region may encode at least one of a reporter protein or fragment thereof, and a marker or selection protein or fragment thereof.
[0030] In another exemplary embodiment, the coding region can encode an antigen or a fragment thereof.
[0031] For example, the antigen may comprise a peptide that is a pathogen antigen, a tumor antigen, or a variant or derivative thereof.
[0032] In yet other exemplary embodiments, the coding region can encode a peptide or fragment thereof for the treatment of a disease.
[0033] In another aspect, a recombinant expression vector is disclosed into which the above-described nucleic acid molecule is inserted.
[0034] In yet another aspect, a method for producing the protein or peptide is disclosed, comprising injecting the nucleic acid molecule described above, or a recombinant expression vector having the nucleic acid molecule inserted therein, into a living body and expressing the protein or peptide from the injected nucleic acid molecule. Effect of the Invention
[0035] The nucleic acid expression platform of the present disclosure is designed to place multiple translational regulatory sequences downstream of the coding region of the open reading frame of the gene of interest. The nucleic acid expression platform can be introduced to stably maintain the expressed transcript in vivo. This allows the application of the nucleic acid expression platform of the present disclosure to improve the efficiency of the final expression of the gene of interest.
[0036] The expression platform can be used to improve the expression efficiency of various genes of interest, such as reporter genes, infectious antigens, tumor antigens, and / or peptides or proteins for therapeutic purposes. Thus, the expression platform of the present disclosure can be used to produce vaccines, such as gene therapy agents, mRNA vaccines, and / or protein subunit vaccines, as well as to detect or analyze the presence or absence of specific substances. [Brief description of the drawings]
[0037] FIG. 1 is a schematic diagram illustrating the structure of a nucleic acid molecule or polynucleotide that can efficiently express a gene of interest according to an exemplary embodiment of the present disclosure.
[0038] FIG. 2 is a schematic diagram illustrating the configuration of a nucleic acid molecule or polynucleotide that can efficiently express a gene of interest according to another exemplary embodiment of the present disclosure.
[0039] 3 and 4 are graphs showing the results of measuring the expression level of Renilla luciferase 6 hours and 24 hours after transfecting a nucleic acid molecule having a coding region encoding Renilla luciferase according to an exemplary embodiment of the present disclosure into Nor10 cells, a mouse muscle-derived cell line.
[0040] 5 and 6 are graphs showing the results of measuring the expression level of Renilla luciferase 6 hours and 24 hours after transforming a nucleic acid molecule having a coding region encoding Renilla luciferase according to an exemplary embodiment of the present disclosure into HeLa cells, a human induced cell line.
[0041] 7 and 8 are graphs showing the results of measuring the expression level of Renilla luciferase 6 hours and 24 hours after transforming a nucleic acid molecule having a coding region encoding Renilla luciferase according to an exemplary embodiment of the present disclosure into 293A cells, a human derived cell line.
[0042] 9 and 10 are graphs showing the results of measuring the expression level of Renilla luciferase 6 hours after injecting a nucleic acid molecule having a coding region encoding Renilla luciferase into a mouse ear according to an exemplary embodiment of the present disclosure.
[0043] 11 and 12 are graphs showing the results of measuring the expression level of Renilla luciferase 6 hours and 24 hours after transforming a nucleic acid molecule having a coding region encoding Renilla luciferase according to an exemplary embodiment of the present disclosure into 293A cells, a human derived cell line.
[0044] In Figures 3 to 12, A to G are used to indicate downstream translation regulatory sequences. The first letter indicates the first downstream translation regulatory element, the second letter indicates the second downstream translation regulatory element, and the third letter indicates the third downstream translation regulatory element. A indicates a translation regulatory element derived from human TNNT1 (SEQ ID NO: 8), B indicates a translation regulatory element derived from human albumin (SEQ ID NO: 9), C indicates a translation regulatory element derived from human FTL (SEQ ID NO: 10), D indicates a translation regulatory element derived from human CCL19 (SEQ ID NO: 11), E indicates a translation regulatory element derived from human AAMP (SEQ ID NO: 12), F indicates a translation regulatory element derived from human RPS27 (SEQ ID NO: 13), and G indicates a translation regulatory element derived from human DEFA5 (SEQ ID NO: 14), each of which is used as a downstream translation regulatory sequence. In addition, the expression level of the peptide or protein expressed from the pHJ5 nucleic acid molecule used as a comparative example was compared. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] Definition of Terms The term "amino acid" is used herein in the broadest sense and is intended to include naturally occurring L-amino acids or residues. Amino acids include not only D-amino acids, but also chemically modified amino acids, such as amino acid analogs, naturally occurring amino acids that do not normally occur in proteins, such as norleucine, and chemically synthesized compounds that have the characteristics of amino acids and properties known in the art. For example, analogs or mimetics of phenylalanine or proline that allow the same stereochemical restriction of peptide compounds as natural Phe or Pro are included within the definition of amino acids. Such analogs and mimetics are referred to herein as "functional equivalents" of amino acids.
[0046] For example, synthetic peptides synthesized by standard solid phase synthesis techniques are not limited to those amino acids encoded by genes, thereby allowing a wider variety of substitutions for a given amino acid. Amino acids not encoded by the genetic code are referred to herein as "amino acid analogs."
[0047] By way of example, amino acid analogs include 2-aminoadipic acid (Aad) for Glu and Asp; 2-aminopimelic acid (Apm) for Glu and Asp; 2-aminobutyric acid (Abu) for Met, Leu and other aliphatic amino acids; 2-aminoheptanoic acid (Ahe) for Met, Leu and other aliphatic amino acids; 2-aminobutyric acid (Aib) for Gly; cyclohexylalanine (Cha) for Val, Leu and Ile; homoarginine (Har) for Arg and Lys; 2,3-diaminopropionic acid (Dap) for Lys, Arg and His; N-ethylglycine (EtGly) for Gly, Pro and Ala; N-ethylglycine (EtGly) for Gly, Pro and Ala; N-ethylasparagine (EtAsn) for Asn and Gln; hydroxylysine (Hyl) for Lys; allohydroxylysine (Ala) for Lys; AHyl); 3-(and 4-)hydroxyproline (3Hyp, 4Hyp) for Pro, Ser and Thr; alloisoleucine (AIle) for Ile, Leu and Val; 4-amidinophenylalanine for Arg; N-methylglycine (MeGly, sarcosine) for Gly, Pro and Ala; N-methylisoleucine (MeIle) for Ile; norvaline (Nva) for Met and other aliphatic amino acids; norleucine (Nle) for Met and other aliphatic amino acids; ornithine (Orn) for Lys, Arg and His; citrulline (Cit) and methionine sulfoxide (MSO) for Thr, Asn and Gln; and N-methylphenylalanine (MePhe), trimethylphenylalanine, halo-(F-, Cl-, Br- or I-)phenylalanine or trifluorylphenylalanine for Phe.
[0048] As used herein, the term "peptide" includes all proteins, protein fragments, and peptides isolated from nature, synthesized by recombinant techniques, or chemically. For example, peptides of the present disclosure are composed of at least 5, and in one example, at least 10 amino acids.
[0049] In certain embodiments, a compound variant, such as a peptide variant having one or more amino acid substitutions, is provided. As used herein, the term "peptide variant" refers to a peptide in which one or more amino acids have been substituted, deleted, added, and / or inserted into the amino acid sequence of the peptide, and which exhibits substantially the same biological function as the peptide composed of the original amino acids. The peptide variant must have an identity of 70% or more, preferably 90% or more, and more preferably 95% or more, with the original peptide.
[0050] Such substitutions may include those known as "conservative" amino acid substitutions. Variants may also include nonconservative changes. In exemplary embodiments, the sequence of a variant polypeptide differs from the original sequence by the substitution, deletion, addition or insertion of five or fewer amino acids. Variants may also be altered by the deletion or addition of amino acids that have minimal effect on the immunogenicity, secondary structure and hydropathic nature of the peptide.
[0051] A "conservative" substitution means that there is no significant change in the secondary structure of a polypeptide when one amino acid is substituted for another. Amino acid variations are obtained on the basis of the relative similarity of the amino acid side-chain substitutes, such as similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature.
[0052] For example, amino acids can be classified by shared side chain properties as follows: 1) hydrophobic (norleucine, methionine, alanine, valine, leucine, isoleucine), 2) neutral hydrophilic (cysteine, serine, threonine, asparagine, glutamine), 3) acidic (aspartic acid, glutamic acid), 4) basic (histidine, lysine, arginine), 5) residues that affect chain direction (glycine, proline), and 6) aromatic (tryptophan, tyrosine, phenylalanine). Conservative substitutions involve exchanging one member of each of these classes for another member of the same class.
[0053] Analysis of the size, shape and type of amino acid side chain substitutions reveals that arginine, lysine and histidine are all positively charged residues; alanine, glycine and serine have similar sizes; phenylalanine, tryptophan and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine are biologically functional equivalents.
[0054] When making mutations, the hydropathic index of amino acids can be taken into consideration. Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamic acid (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
[0055] The hydrophobic amino acid index is very important in imparting interactive biological functions to proteins. It is a known fact that substitution with an amino acid having a similar hydrophobic index can retain similar biological activity. When introducing a mutation with reference to the hydrophobic index, substitution is preferably performed between amino acids showing a difference in hydrophobic index within ±2, more preferably within ±1, and even more preferably within ±0.5.
[0056] It is also well known that substitutions between amino acids with similar hydrophilicity values result in proteins with equivalent biological activity. The following hydrophilicity values have been assigned to each amino acid residue: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0±1); glutamic acid (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5±1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); lysine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). When mutations are introduced with reference to the hydrophilicity value, substitutions are made between amino acids showing a difference in hydrophilicity value within ±2, more preferably within ±1, and more preferably within ±0.5.
[0057] Amino acid exchanges in proteins that do not globally alter the activity of the molecule are well known in the art (H. Neurath, R.L. Hill, The Proteins, Academic Press, New York, 1979). The most commonly occurring exchanges are between the amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly.
[0058] Generally, the peptides (including fusion proteins) and polynucleotides referred to herein are isolated. An "isolated" peptide or polynucleotide is one that has been removed from its original environment. For example, a protein present in a natural state is isolated by removing all or part of the substances with which it is present in that state. Such polypeptides should be at least 90% pure, preferably 95%, and more preferably 99% pure. Polynucleotides are isolated by cloning in a vector. Recombinant peptides encoded by the nucleotide sequences referred to herein above can be readily produced by known methods using any of the many known expression vectors. Expression can be in a suitable host cell transformed with an expression vector containing a DNA sequence encoding the recombinant protein. Suitable host cells include prokaryotes, yeast and eukaryotes. By way of example, the host cells can be yeast, insect cells or eukaryotic derived cell lines such as mammalian cell lines (such as Cos or CHO).
[0059] As used herein, "polynucleotide" or "nucleic acid" are used interchangeably and refer to a polymer of nucleotides of any length, and include DNA (e.g., cDNA) and RNA molecules. A "nucleotide," which is a building block of a nucleic acid molecule, can be a deoxyribonucleotide, a ribonucleotide, a modified nucleotide or base, and / or its analogue, or any substrate that can be incorporated into a polymer by a DNA or RNA polymerase or by a synthetic reaction. A polynucleotide may include modified nucleotides, sugar- or base-modified analogues, such as methylated nucleotides and their analogues.
[0060] Some mutations in nucleotides do not result in mutations in proteins. Such nucleic acids include nucleic acid molecules that contain functionally equivalent codons or codons that code for the same amino acid (e.g., due to codon degeneracy, there are six codons for arginine or serine), or codons that code for biologically equivalent amino acids. Mutations in nucleotides can also result in changes in the protein itself. Mutations that result in changes in the amino acids of proteins can also result in proteins that exhibit approximately the same activity as the proteins of the present disclosure.
[0061] It is clear to those skilled in the art that the peptides and nucleic acid molecules of the present disclosure are not limited to the amino acid or base sequences listed in the sequence listing, so long as they have the characteristics of the nucleic acid molecules or polynucleotides of the present disclosure, such as the effect as a vaccine and / or immune enhancer. For example, a biologically functional equivalent that may be included in a coding region operably linked to an expression control sequence and / or a recombinant protein / peptide expressed therefrom may be a polynucleotide having a mutation in the base sequence and / or a protein / peptide having a mutation in the amino acid sequence that exhibits a biological activity equivalent to that of the coding region and / or recombinant protein described above.
[0062] Considering the above-mentioned biologically equivalent activity variants, the nucleic acid molecules encoding peptides and / or proteins are also understood to include sequences that show substantial identity with the sequences listed in the sequence listing. The substantial identity means a sequence that shows at least 61% homology, more preferably 70% homology, even more preferably 80% homology, and most preferably 90% homology when the sequences of the present disclosure described above are aligned to any other sequence for maximum correspondence and the aligned sequences are analyzed using algorithms commonly used in the art. Alignment methods for sequence comparison are well known in the art. As used herein, the term "vector" refers to a construct that can be delivered to a host cell, preferably capable of expressing one or more genes or sequences of interest. For example, vectors include viral vectors, DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors linked to CCA (cationic condensing agents), DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells such as producer cells.
[0063] As used herein, "expression control / regulation sequence" or "expression control / regulation element" may refer to a nucleic acid sequence that regulates the transcription of a nucleic acid molecule and / or the translation of a nucleic acid in the form of a transcript. In addition, "transcription control / regulation sequence" or "transcription control / regulation element" refers to a nucleic acid sequence that regulates the transcription of a nucleic acid. Transcription control elements include promoters, such as a constitutive promoter or an inducible promoter, or enhancers.
[0064] The terms "translation control / regulation sequence" or "translation control / regulation element" can also be used for nucleic acid sequences that regulate the translation of a nucleic acid in the form of a transcript into a protein or peptide. These expression control sequences / elements, transcriptional regulatory sequences / elements and / or translational regulatory sequences / elements are operatively linked to the sequence to be expressed, e.g., the nucleic acid sequence to be transcribed or translated.
[0065] As used herein, the term "operatively linked" refers to a functional connection between a nucleic acid expression control sequence (e.g., a promoter, a signal sequence, a ribosome binding site, a transcription termination sequence, etc.) and another nucleic acid sequence, whereby the control sequence controls the transcription and / or translation of the other nucleic acid sequence.
[0066] nucleic acid molecule The present disclosure is based on a nucleic acid molecule-based expression platform or expression system, such as a nucleic acid molecule having improved expression efficiency of a coding region operably linked to an expression regulatory sequence and a vector containing the same. Figure 1 is a schematic diagram showing the structure of a nucleic acid molecule or polynucleotide that can efficiently express a gene of interest according to an exemplary embodiment of the present disclosure.
[0067] As shown in FIG. 1, the nucleic acid molecule may include a translation control element (TLCE) including a nucleotide sequence having translation initiation activity, and a coding region (CR) operably linked to the translation control element (TLCE) and including an open reading frame (ORF) of a gene of interest (GOI).
[0068] Optionally, the nucleic acid molecule may comprise at least one nucleotide sequence of a polyadenylation signal sequence or a polyadenosine sequence (PA) located downstream of a transcriptional regulatory element (TCCE) and / or a translational regulatory element (TLCE) operably linked to the coding region (CR).
[0069] The translational regulatory element (TLCE) may include a nucleotide sequence having a translation initiation activity operably linked to the coding region (CR) inserted in the form of an open reading frame (ORF). For example, the translational regulatory element (TLCE) may include an upstream translational regulatory element (U-TLCE) located upstream of the coding region (CR) and / or a downstream translational regulatory element (D-TLCE) located downstream of the coding region (CR).
[0070] In other words, the upstream translational regulatory element (U-TLCE) can be located upstream of the coding region (CR), and the downstream translational regulatory element (D-TLCE) can be located downstream of the coding region (CR). In other words, the coding region (CR) can be located between the upstream translational regulatory element (U-TLCE) and the downstream translational regulatory element (D-TLCE), forming a target sequence (TS) consisting of the open reading frame of the gene of interest.
[0071] The upstream translational regulatory element (U-TLCE) can be all or a part of a 5'-untranslated region (5'-UTR) that has cap-dependent translation initiation activity.
[0072] Most eukaryotic mRNAs have 7-methyl-guanosine (cap, m7G) at the 5' end, but the translation initiation complex recognizes the cap at the 5' end and advances to the initiation codon AUG to start protein synthesis. In other words, the cap structure at the 5' end of mRNA not only initiates protein synthesis, but also protects mRNA from destruction by the action of nuclease.
[0073] For example, the first step of in vitro transcription is to linearize pDNA (plasmid DNA) by treating it with a restriction enzyme, and then use an appropriate RNA polymerase to produce a capped mRNA by attaching m7G(5')-ppp(5')G (called a regular cap analog). Alternatively, in vitro transcription can be performed without a cap analog, and the cap reaction can be performed using a commercially available capping enzyme derived from vaccinia virus, and an "anti-reverse" cap analog (ARCA) that prevents such a cap reaction can be used. When ARCA is introduced, only the 3'-O-methylated guanosine nucleotide that has undergone methylation can be bound to the nucleotide of the unmethylated guanosine.
[0074] Exemplary modified 5'-Cap structures are Cap1 (methylation of the ribose in the nucleotide adjacent to m7G), Cap2 (methylation of the ribose of the nucleotide located second downstream of m7G), Cap3 (methylation of the ribose of the nucleotide located third downstream of m7G), Cap4 (methylation of the ribose of the nucleotide located fourth downstream of m7G), ARCA (anti-reverse cap analog, modified ARCA (e.g., phosphorothioate modified ARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-diaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.
[0075] For example, the upstream translational regulatory element (U-TLCE) and / or the downstream translational regulatory element (D-TLCE) may each be composed of a nucleotide sequence having cap-dependent translation initiation activity derived from an animal, for example, a mammal, specifically, a primate, more specifically, a human, or a transcript sequence thereof. The upstream translational regulatory element (U-TLCE) is a region to which a translation initiation complex binds during the translation process of a peptide and / or protein expressed from the coding region (CR), and may be a cis-acting nucleotide sequence that induces the translation of the coding region (CR).
[0076] When the upstream translational regulatory element (U-TLCE) is a whole or part of a nucleotide sequence having cap-dependent translation initiation activity, it may contain a downstream translational regulatory element (D-TLCE) located downstream of the coding region (CR). A nucleic acid molecule containing an upstream translational regulatory element (U-TLCE) and a downstream translational regulatory element (D-TLCE) can further improve the expression efficiency of an open reading frame (ORF) constituting the coding region (CR). In other words, the upstream translational regulatory element (U-TLCE) and the downstream translational regulatory element (D-TLCE) improve the translation efficiency of the open reading frame of the gene of interest (GOI) forming the coding region (CR) or its transcript, and play an important role in stably maintaining the mRNA, which is the transcript, in the cell without being destroyed.
[0077] In exemplary embodiments, the upstream translational regulatory element (U-TLCE) may include, but is not limited to, a translational regulatory element derived from any one selected from the group consisting of human troponin T1, slow backbone type (human TNNT1), human albumin (human ALB), human ferritin light chain (human FTL), human CC motif chemokine ligand 19 (human CCL19), human vascular-associated migratory cell protein (human AAMP), human ribosomal protein S27 (human RPS27) and human defensin alpha 5 (human DEFA5).
[0078] For example, an upstream translational regulatory element (U-TLCE) from human TNNT1 may comprise a translational regulatory element of SEQ ID NO: 1, or a transcript sequence thereof. An upstream translational regulatory element (U-TLCE) from human ALB may comprise a translational regulatory element of SEQ ID NO: 2, or a transcript sequence thereof. An upstream translational regulatory element (U-TLCE) from human FTL may comprise a translational regulatory element of SEQ ID NO: 3, or a transcript sequence thereof. An upstream translational regulatory element (U-TLCE) from human CCL19 may comprise a translational regulatory element of SEQ ID NO:4 or a transcript sequence thereof. An upstream translational regulatory element (U-TLCE) from human AAMP may comprise a translational regulatory element of SEQ ID NO:5 or a transcript sequence thereof. An upstream translational regulatory element (U-TLCE) from human RPS27 may comprise a translational regulatory element of SEQ ID NO:6 or a transcript sequence thereof. An upstream translational regulatory element (U-TLCE) from human DEFA5 may comprise a translational regulatory element of SEQ ID NO:7 or a transcript sequence thereof. However, an upstream translational regulatory element (U-TLCE) is not limited to a particular nucleotide sequence or a transcript sequence thereof.
[0079] The downstream translational regulatory element (D-TLCE) may consist of a first downstream translational regulatory element (D-TLCE1) and a second downstream translational regulatory element (D-TLCE2) that are inserted sequentially downstream of the coding region (CR). The first downstream translational regulatory element (D-TLCE1) and the second downstream translational regulatory element (D-TLCE2) may be the same or different from each other.
[0080] As an example, the first downstream translational regulatory element (D-TLCE1) and the second downstream translational regulatory element (D-TLCE2) may each independently comprise a downstream translational regulatory element derived from any one selected from the group consisting of human TNNT1, human ALB, human FTL, human CCL19, human AAMP, human RPS27 and human DEFA5.
[0081] For example, the first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human TNNT1 may each comprise a translational regulatory element of SEQ ID NO: 7 or a transcript sequence thereof. The first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human ALB may each comprise a translational regulatory element of SEQ ID NO: 9 or a transcript sequence thereof. The first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human FTL may each comprise a translational regulatory element of SEQ ID NO: 10 or a transcript sequence thereof. The first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human CCL19 may each comprise a translational regulatory element of SEQ ID NO: 11 or a transcript sequence thereof. The first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human AAMP may each comprise a translational regulatory element of SEQ ID NO: 12 or a transcript sequence thereof. The first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human RPS27 may comprise the translational regulatory element of SEQ ID NO: 13 or its transcript sequence. The first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) from human DEFA5 may comprise the translational regulatory element of SEQ ID NO: 14 or its transcript sequence. However, the first and second downstream translational regulatory elements (D-TLCE1, D-TLCE2) are not limited to a particular nucleotide sequence or its transcript sequence.
[0082] In an exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element derived from human TNNT1 or a transcript sequence thereof, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human ALB, human FTL, human CCL19, human AAMP, human RPS27, and human DEFA5 or a transcript sequence thereof. For example, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human TNNT1 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may be derived from any one selected from the group consisting of human FTL, human CCL19, and human DEFA5.
[0083] In alternative embodiments, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof from human TNNT1, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element or a transcript sequence thereof from human FTL or human CCL19. In other alternative embodiments, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof from human TNNT1, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element or a transcript sequence thereof from human CCL19 or human RPS27.
[0084] In other exemplary embodiments, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element derived from human ALB or its transcript sequence, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from human DEFA5 or its transcript sequence.
[0085] In yet another exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element derived from human FTL or a transcript sequence thereof, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, human RPS27, and human DEFA5 or a transcript sequence thereof. For example, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human FTL or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, said human RPS27, and said human DEFA5 or a transcript sequence thereof.
[0086] In an alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human FTL or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, and human RPS27 or a transcript sequence thereof. In another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human FTL or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from human FTL or a transcript sequence thereof.
[0087] In yet another exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element derived from human CCL19 or a transcript sequence thereof, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, human CCL19, human RPS27, and human DEFA5 or a transcript sequence thereof. For example, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human CCL19 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from any one selected from the group consisting of human FTL, human CCL19, human RPS27, and said human DEFA5.
[0088] In an alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof from human CCL19, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element or a transcript sequence thereof from human FTL or human RPS27. In another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof from human CCL19, the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element or a transcript sequence thereof from human CCL19. In yet another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof from human CCL19, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element or a transcript sequence thereof from human CCL19 or human RPS27.
[0089] In yet another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human CCL19 or its transcript sequence, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element derived from human FTL or human CCL19 or its transcript sequence.
[0090] In yet another exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element derived from human AAMP or its transcript sequence, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human ALB, human FTL, human RPS27 and human DEFA5, or its transcript sequence.
[0091] In yet another exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element or a transcript sequence thereof derived from human RPS27, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human TNNT1, human ALB, human FTL, human CCL19, human AAMP, human RPS27, and human DEFA5. For example, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof derived from human RSP27, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human TNNT1, human FTL1, human CCL19, human AAMP, human RPS27, and human DEFA5.
[0092] In an alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human RSP27 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from any one selected from the group consisting of human FTL, human CCL19, human RPS27 and said human DEFA5 or a transcript sequence thereof. In another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human RSP27 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from any one selected from the group consisting of human FTL, human RPS27 and human DEFA5 or a transcript sequence thereof.
[0093] In another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human RSP27 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, human RPS27 and human DEFA5 or a transcript sequence thereof. In yet another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human RSP27 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element derived from human RPS27 or human DEFA5 or a transcript sequence thereof. In yet another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human RSP27 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element derived from human FTL or a transcript sequence thereof.
[0094] In yet another exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a downstream translational regulatory element derived from human DEFA5 or a transcript sequence thereof, and the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one of the group consisting of human TNNT1, human ALB, human FTL, human CCL19, human AAMP, and human RPS27 or a transcript sequence thereof. For example, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human DEFA5 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a lower translational regulatory element derived from any one of the group consisting of human TNNT1, human ALB, the human FTL, human AAMP, and human RPS27 or a transcript sequence thereof.
[0095] In an alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof derived from human DEFA5, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human ALB, human FTL, human AAMP, and human RPS27. In another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element or a transcript sequence thereof derived from human DEFA5, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human ALB, human FTL, and human RPS27.
[0096] In yet another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human DEFA5 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from any one selected from the group consisting of human FTL, human CCL9, human AAMP, and human RPS27 or a transcript sequence thereof. In yet another alternative embodiment, when the first downstream translational regulatory element (D-TLCE1) comprises a downstream translational regulatory element derived from human DEFA5 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a downstream translational regulatory element derived from human FTL or human RPS27 or a transcript sequence thereof.
[0097] The coding region (CR) is not particularly limited if it contains the open reading frame (ORF) of the intended gene of interest (GOI). In an exemplary embodiment, the coding region (CR) can be composed of an open reading frame (ORF) that is a nucleotide sequence or a transcript sequence that encodes at least one of a reporter protein or a fragment thereof, a marker or a selection protein or a fragment thereof, an antigen or a fragment thereof, and a protein or a fragment thereof for treating a disease.
[0098] By way of example, the coding region (CR) may consist of an open reading frame (ORF) encoding a reporter protein / reporter peptide or a fragment thereof, such as a luciferase protein (e.g., renilla luciferase), Green Fluorescent Protein (GFP), Enhanced Green Fluorescent Protein (EGFP), a glucuronidase, such as beta-glucuronidase, and / or a galactosidase, such as beta-galactosidase.
[0099] In one exemplary embodiment, the coding region (CR) can consist of an open reading frame encoding a marker or selection protein / peptide or fragment thereof, such as globin proteins, such as alpha-globin and / or beta-globin, galactokinase and / or hypoxanthine guanine phosphoribosyltransferase, etc. Additionally, open reading frames (ORFs) encoding other reporter proteins / peptides and / or marker or selection proteins / peptides can be inserted into the coding region (CR).
[0100] In other exemplary embodiments, the antigen gene inserted into the coding region (CR) may consist of an open reading frame (ORF) encoding a protein / peptide, including a pathogenic antigen or fragment thereof, a tumor antigen, or a variant or derivative thereof.
[0101] Pathogenic antigens are derived from pathogenic organisms, particularly bacterial, viral or protozoan (multicellular) pathogenic organisms, that elicit an immunological response in an individual, particularly a mammalian individual, more particularly a human. More specifically, a pathogenic antigen can be a surface antigen, e.g., a protein (or a fragment of a protein, e.g., an external portion of a surface antigen), located on the surface of a virus or bacterial or protozoan organism.
[0102] By way of example, a pathogenic antigen can be a peptide or protein antigen derived from a pathogen associated with an infectious disease. More specifically, the pathogenic antigens include Acinetobacter baumannii, Anaplasma genus, Anaplasma phagocytophilum, Ancylostoma braziliense, Ancylostoma duodenale, Arcanobacterium haemolyticum, Ascaris lumbricoides, Aspergillus genus, Astroviridae, Babesia genus, Bacillus anthracis, Bacillus cereus, Bartonella henselae, and others. henselae, BK virus, Blastocystis hominis, Blastomyces dermatitidis, Bordetella pertussis, Borrelia burgdorferi, Borrelia genus, Borrelia spp, Brucella genus, Brugia malayi, Bunyaviridae family, Burkholderia cepacia and other Burkholderia species, Burkholderia mallei, Burkholderia pseudomallei, Caliciviridae family, Campylobacter genus, Candida albicans, Candida spp, Chlamydia trachomatistrachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, CJD prion, Clonorchis sinensis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium difficile, Clostridium spp, Clostridium tetani, Coccidioides spp, coronaviruses, Corynebacterium diphtheria, Coxiella burnetii burnetii, Crimean-Congo hemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium genus, Cytomegalovirus (CMV), Dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4), Dientamoeba fragilis, Ebolavirus (EBOV), Echinococcus genus, Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia genus, Entamoeba histolytica, Enterococcus genus, Enterovirus genus, Enteroviruses, mainly Coxsackie A virusesvirus and Enterovirus 71 (EV71), Epidermophyton spp, Epstein-Barr Virus (EBV), Escherichia coli O157:H7, O111 and O104:H4, Fasciola hepatica and Fasciola gigantica, FFI prions, Filarioidea superfamily, Flaviviruses, Francisella tularensis, Fusobacterium genus, Geotrichum candidum, Giardia intestinalis, Gnathostoma spp, GSS prions, Guanarito viruses virus, Haemophilus ducreyi, Haemophilus influenza, Helicobacter pylori, Henipavirus (Hendra virus Nipah virus), Hepatitis A virus, Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis D virus, Hepatitis E virus, Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), Histoplasma capsulatum, HIV (Human immunodeficiency virus), Hortaea werneckii, Human bocavirus (HBoV), Human herpesvirus 6 (HHV-6) and Human herpesvirus 7 (HHV-7), Human metapneumovirus (Human metapneumovirus (hMPV), human papillomavirus (HPV), human parainfluenza virus (HPV)HPIV, Japanese encephalitis virus, JC virus, Junin virus, Kingella kingae, Klebsiella granulomatis, Kuru prion, Lassa virus, Legionella pneumophila, Leishmania genus, Leptospira genus, Listeria monocytogenes, Lymphocytic choriomeningitis virus (LCMV), Machupo virus, Malassezia spp., Marburg virus, Measles virus virus, Metagonimus yokogawai, Microsporidia phylum, Molluscum contagiosum virus (MCV), Mumps virus, Mycobacterium leprae and Mycobacterium lepromatosis, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Naegleria fowleri, Necator americanus, Neisseria gonorrhoeae, Neisseria meningitidis meningitides, Nocardia asteroids, Nocardia spp, Onchocerca volvulusvolvulus, Orientia tsutsugamushi, Orthomyxoviridae family (influenza), Paracoccidioides brasiliensis, Paragonimus spp., Paragonimus westermani, Parvovirus B19, Pasteurella genus, Plasmodium genus, Pneumocystis jirovecii, Poliovirus, Rabies virus, Respiratory syncytial virus (RSV), Rhinovirus, Rickettsia akari akari, Rickettsia genus, Rickettsia prowazekii, Rickettsia rickettsia, Rickettsia typhi, Rift Valley fever virus, Rotavirus, Rubella virus, Sabia virus, Salmonella genus, Sarcoptes scabiei, SARS coronavirus, Schistosoma genus, Severe fever with thrombocytopenia syndrome virus (SFTSV), Shigella genus, Sin Nombre virus virus, Hantavirus, Sporothrix schenckii, Staphylococcusgenus, Staphylococcus genus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Strongyloides stercoralis, Taenia genus, Taenia solium, Tickborne encephalitis virus (TBE) V), Toxocara canis or Toxocara cati, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp, Trichuris trichiura, Trypanosoma brucei, Trypanosoma cruzi, Ureaplasma urealyticum, Varicella zoster virus (VZV), Variola major or Variola minor The viral vectors may be derived from, but are not limited to, Vibrio minor, vCJD prion, Venezuelan equine encephalitis virus, Vibrio cholera, West Nile virus, Western equine encephalitis virus, Wuchereria bancrofti, Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis.
[0103] In an alternative aspect, the coding region (CR) can consist of an open reading frame (ORF) encoding a protein or peptide that is a tumor antigen or a fragment, variant or derivative thereof. The tumor antigen can be a melanocyte-specific antigen, a testicular cancer antigen or a tumor-specific antigen, such as a CT-X antigen, a non-CT-X antigen, a binding partner for a CT-X antigen or a binding partner for a non-CT-X antigen or a tumor-specific antigen, or a tumor-specific antigen, a variant or derivative of a tumor antigen.
[0104] Open reading frames (ORFs) encoding such tumor antigens include 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1, alpha-5-beta-1-integrin, alpha-5-beta-6-integrin, alpha-actinin-4 / m, alpha-methylacyl-coenzyme A racemase, ART-4, ARTC1 / m, B7H4, BAGE-1, BCL-2, bcr / abl, beta-catenin / m, BING-4, BRCA1 / m, BRCA2 / m, CA 15-3 / CA 27-29, CA19-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8 / m, cathepsin B, and IL-1. B), cathepsin L, CD19, CD20, CD22, CD25, CDE30, CD33, CD4, CD52, CD55, CD56, CD80, CDC27 / m, CDK4 / m, CDKN2A / m, CEA, CLCA2, CML28, CML66, COA-1 / m, coactosin-like protein, collageXXIII, COX-2, CT-9 / BRD6, Cten, cyclin B1, cyclin D1, cyp-B, CYPB1, DAM-10, DAM-6, DEKCAN, EFTUD2 / m, EGFR, ELF2 / m, EMMPRIN, EpCam, EphA2, EphA3, ErbB3, ETV6-AML1, EZH2, FGF-5, FN, Frau-1, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE7b, GAGE-8, GDEP, GnT-V, gp100, GPC3, GPNMB / m, HAGE, HAST-2, hepsin, Her2 / neu, HERV-K-MEL, HLA-A*0201-R17I, HLA-A1 1 / m, HLA-A2 / m, HNE, Homeobox NKX3.1, HOM-TES-14 / SCP-1, HOM-TES-85, HPV-E6, HPV-E7, HSP70-2M, HST-2, hTERT, iCE, IGF-1 R, IL-13Ra2, IL-2R, IL-5, immature laminin receptor, kallikrein-2, krein-4, Ki67, KIAA0205, KIAA0205 / m, KK-LC-1, K-Ras / m, LAGE-A1, LDLR-FUT, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-B1, MAGE-B2, MAGE- B3, MAGE-B4, MAGE-B5, MAGE-B6, MAGE-B10, MAGE-B16, MAGE-B17, MAGE-C1, MAGE-C2, MAGE-C3, MAGE-D1, MAGE-D2, MAGE-D4, MAGE-E1, MAGE-E2, MAGE-F1, MAGE-H1, MAGEL2, mammaglobin A, MART-1 / melan-A, MART-2, MART-2 / m, matrix protein 22, MC1R, M-CSF, ME1 / m, mesothelin, MG50 / PXDN, MMP11, MN / CAIX-antigen, MRP-3, MUC-1, MUC-2, MUM-1 / m, MUM-2 / m, MUM-3 / m, myosin class I / m, NA88-A, N-acetylglucosaminyltransferase-V, neo-PAP, neo-PAP / m, NFYC / m, NGEP, NMP22, NPM / ALK, N-Ras / m, NSE, NY-ESO-1, NY-ESO-B, OA1, OFA-iLRP, OGT, OGT / m, OS-9, OS-9 / m, Osteocalcin, osteopontin, p15, p190minor, bcr-abl, p53, p53 / m, PAGE-4, PAI-1, PAI-2, PAP, PART-1, PATE, PDEF, Pim-1-kinase, Pin-1, Pml / PARalpha, POTE, PRAME, PRDX5 / m, prostein, proteinase-3, PSA, PSCA, PSGR, PSM, PSMA, PTPRK / m, RAGE-1, RBAF600 / m, RHAMM / CD168, RU1, RU2, S-100, SAGE, SART-1, SART-2, SART-3, SCC, SIRT2 / m, Sp17, SSX-1, SSX-2 / HOM-MEL-40, SSX- 4, STAMP-1, STEAP-1, survivin, survivin-2B, SYT-SSX-1, SYT-SSX-2, TA-90, TAG-72, TARP, TEL-AML1, TGF beta, TGF beta RII, TG It may consist of, but is not limited to, nucleotide sequences encoding or transcript sequences encoding M-4, TPI / m, TRAG-3, TRG, TRP-1, TRP-2 / 6b, TRP / INT2, TRP-p8, tyrosinase, UPA, VEGFR1, VEGFR-2 / FLK-1, WT1 and lymphocytic blood cell immunoglobulin genotype or lymphocytic blood cell T cell receptor genotype, or fragments, variants or derivatives thereof.
[0105] In yet other exemplary embodiments, the coding region (CR) may consist of an open reading frame (ORF) encoding a protein / peptide that is a therapeutic protein / peptide or a fragment, variant or derivative thereof.
[0106] Therapeutic proteins can play an important role in the generation of therapeutic agents capable of modifying and treating genetic defects, destroying cancer cells or pathogen-infected cells, treating immune system disorders, treating metabolic or endocrine disorders. By way of example, therapeutic proteins can be used for various purposes, including the treatment of various disorders, such as infectious disorders, neoplasms (e.g., cancer or tumor disorders), disorders of the blood and blood-forming organs, endocrine, nutritional and metabolic disorders, nervous system disorders, circulatory system disorders, respiratory system disorders, digestive system disorders, skin and subcutaneous tissue disorders, musculoskeletal and connective tissue disorders, and genitourinary system disorders, independently of whether they are genetic or acquired.
[0107] For example, proteins that can be used to treat metabolic or endocrine disorders (specific disorders for which protein therapy is used) include Acid sphingomyelinase (Niemann-Pick disease), Adipotide (obesity), Agalsidase-beta (human galactosidase A) (Fabry disease; prevents accumulation of lipids that lead to renal and cardiovascular complications), Alglucosidase (Pompe disease; glycogen storage disease type II), alpha-galactosidase A (alpha-GAL A, agalsidase alpha) (Fabry disease), alpha-glucosidase (glycogen storage disease (GSD), Morbus Pompe disease), alpha-L-iduronidase (mucopolysaccharidoses (MPS), Hurler syndrome), syndrome, Scheie syndrome), alpha-N-acetylglucosaminidase (Sanfilippo syndrome), Amphiregulin (cancer, metabolic disease), Angiopoietin (Ang1, Ang2, Ang3, Ang4, ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL5, ANGPTL6, ANGPTL7) (angiogenesis, vascular stability), Betacellulin (metabolic disease), Beta-glucuronidase (Sly syndrome), Bone morphogenetic protein (BMP) protein), BMPs (BMP1, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10, BMP15) (regenerative effects, bone-related conditions, chronic kidney disease (CKD)), CLN6 protein (CLN6 disease - atypical late infantile, late onset variants)Variant), Early Juvenile, Neuronal Ceroid Lipofuscinosis (NCL), Epidermal Growth Factor (EGF) (Wound healing, Regulation of cell growth, proliferation and differentiation), Epigen (Metabolic Disorders), Epiregulin (Metabolic Disorders), Fibroblast Growth Factor (Fibroblast Growth Factor) Factor) (FGF, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23) (Wound healing, Angiogenesis, Endocrine disorders, Tissue regeneration), Galsulphase (Mucopolysaccharidosis type VI), Ghrelin (Irritable bowel syndrome, IBS, Obesity, Prader-Willi syndrome, Type 2 diabetes mellitus) mellitus, Glucocerebrosidase (Gaucher's disease), GM-CSF (regenerative effects, white blood cell production, cancer), Heparin-binding EGF-like growth factor (HB-EGF) (wound healing, cardiac hypertrophy and cardiac development and function), Hepatocyte growth factor (HGF) (hepatocyte growth factor-like growth factor), Hepatocyte growth factor (HGF) (regenerative effect, wound healing), Hepcidin (iron metabolism disorder, beta-thalassemia), Human albumin (decreased production of albumin (hypoproteinemia), decreased production of increased albumin (renal syndrome, hypovolemia, hyperbilirubinemia), Idursulfase (iduronate-2-sulfatase) (Mucopolysaccharidosis type II (Hunter syndrome, Hunter syndrome)syndrome), integrins αVβ3, αVβ5 and α5β1 (Bind matrix macromolecules and proteinases, angiogenesis), iduronate sulfatase (Hunter syndrome), laronidase (Hurler and Hurler-Scheie forms of mucopolysaccharidosis type I), N-acetylgalactosamine-4-sulfatase (rhASB; galsulfase, arylsulfatase A (ARSA), arylsulfatase B (ARSB)) (arylsulfatase B deficiency, Maroteaux-Lamy syndrome, mucopolysaccharidosis type VI), N-acetylglucosamine-6-sulfatase (Sanfilippo syndrome), syndrome), nerve growth factor (NGF, Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), and Neurotrophin 4 / 5 (NT-4 / 5) (regenerative effects, cardiovascular disease, coronary angioplasty, coronary atherosclerosis, obesity, type 2 diabetes mellitus, metabolic syndrome, acute coronary syndrome, dementia, depression, schizophrenia, autism, Rett syndrome, anorexia nervosa, bulimia nervosa, nervosa), wound healing, skin ulcers, corneal ulcers, Alzheimer's disease), Neuregulin (NRG1, NRG2, NRG3, NRG4) (metabolic diseases, schizophrenia), Neuropilin (NRP-1, NRP-2) (angiogenesis, axon guidance) guidance), cell survival, migration), obestatin (irritable bowel syndrome)syndrome, IBS), obesity, Prader-Willi syndrome, type 2 diabetes mellitus), Platelet Derived Growth Factor (PDGF (PDFF-A, PDGF-B, PDGF-C, PDGF-D) (regenerative effects, wound healing, angiogenic diseases, arteriosclerosis, fibrosis, cancer), TGF beta receptors (endoglin, TGF-beta 1 receptor, TGF-beta 2 receptor, TGF-beta 3 receptor) (renal fibrosis, kidney disease, diabetes, end-stage renal disease (ESRD), angiogenesis), Thrombopoietin (THPO) (Megakaryocyte Growth and Development Factor (MGDF)) (platelet disorders, platelets for donation, recovery of platelet counts after myelosuppressive chemotherapy, Transforming Growth Factor (TGF)) (platelet disorders, platelets for donation, recovery of platelet counts after myelosuppressive chemotherapy, factor) (TGF (TGF-alpha, TGF-beta (TGF-beta1, TGF-beta2, and TGF-beta3)) (regenerative effects, wound healing, immunity, cancer, heart disease, diabetes, Marfan syndrome, Loeys-Dietz syndrome), VEGF (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and PIGF) (regenerative effects, angiogenesis, wound healing, cancer, permeability), Nesiritide (Acute decompensated congestive heart failure), Trypsin (Decubitus ulcer, varicose ulcer, debridement of eschar, dehiscent wound) wound, sunburn, meconium ileus), adrenocorticotrophic hormone (ACTH) (Addison's disease, small cell carcinoma, adrenoleukodystrophy, congenital adrenal hyperplasia)hyperplasia, Cushing's syndrome, Nelson's syndrome, infantile spasms), Atrial-natriuretic peptide (ANP) (endocrine disorders), Cholecystokinin (various), Gastrin (hypogastrinemia), Leptin (diabetes, hypertriglyceridemia, diabetes), Oxytocin (stimulation of breastfeeding, non-progression of labour), Somatostatin (symptomatic treatment of carcinoid syndrome, acute variceal bleeding) bleeding, and acromegaly, polycystic disease of the liver and kidneys, acromegaly and symptoms due to neuroendocrine tumors), vasopressin (antidiuretic hormone) (diabetes insipidus), calcitonin (postmenopausal osteoporosis, hypercalcaemia, Paget's disease, bone metastases, phantom limb pain, spinal stenosis), exenatide (type 2 diabetes resistant to treatment with metformin and sulphonylureas), growth hormone (GH), somatotropin (growth failure due to GH deficiency or chronic renal insufficiency), Prader-Willi syndrome, Turner syndrome, AIDS wasting wasting or cachexia with antiviral therapy), insulin (diabetes mellitus, diabetic ketoacidosisketoacidosis, hyperkalaemia), insulin-like growth factor 1, IGF-1 (childhood growth failure due to GH gene deficiency or severe primary IGF1 deficiency, neurodegenerative disease, cardiovascular disease, heart failure), mecasermin rinfabate, IGF-1 analog (GH gene deficiency or Childhood growth failure due to severe congenital IGF1 deficiency, neurodegenerative disease, cardiovascular disease, heart failure), Mecasermin, IGF-1 analogues (Childhood growth failure due to GH gene deficiency or severe congenital IGF1 deficiency, neurodegenerative disease, cardiovascular disease, heart failure), Pegvisomant (Acromegaly), Pramlintide (Diabetes mellitus, in combination with insulin), Teriparatide (Human parathyroid hormone residues 1-34) (Severe osteoporosis), Becaplermin (Debridement adjunct for diabetic ulcers), Dibotermin-alpha (Bone morphogenetic protein 2) (Spinal fusion) These may include, but are not limited to, histrelin acetate (gonadotropin releasing hormone; GnRH) (precocious puberty), octreotide (symptomatic relief of acromegaly, VIP-secreting adenomas and metastatic carcinoid tumours), and palifermin (keratinocyte growth factor; KGF) (severe oral mucositis, wound healing in patients undergoing chemotherapy).
[0108] In addition, proteins related to blood diseases, circulatory system diseases, respiratory diseases, cancer or tumor diseases, infectious diseases or immune deficiencies (specific diseases for which protein therapeutics are used) are: Alteplase (tissue plasminogen activator; tPA) (Pulmonary embolism, myocardial infarction, acute ischaemic stroke, occlusion of central venous access devices), Anistreplase (thrombolysis), Antithrombin III (AT-III) (genetic AT-III deficiency, thromboembolism), Bivalirudin (reduction of blood clotting risk in coronary angioplasty and heparin-induced thrombocytopenia), Darbepoetin-alpha (chronic renal insufficiency and chronic renal failure), Drotrecogin-alpha (activated protein C) (severe sepsis with high mortality), Erythropoietin, Epoetin-alpha, erythropoietin (anemia of chronic disease, myelodysplasia, anemia due to renal failure or chemotherapy, preoperative preparation), Factor IX (Haemophilia B), Factor VIIa (bleeding in patients with hemophilia A or B and inhibitors to factor VIII or factor IX), Factor VIII (Haemophilia A), Lepirudin (heparin-induced hypothrombocytosis), Protein C concentrate (venous thrombosis, Purpura fulminans)fulminans), Reteplase (deletion mutation of tPA) (regulation of acute myocardial infarction, enhancement of left ventricular function), Streptokinase (acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or embolism, occlusion of arteriovenous cannula), Tenecteplase (acute myocardial infarction), Urokinase (pulmonary embolism), Angiostatin (cancer), anti-CD22 immunotoxin (relapsed CD33+ acute myeloid leukemia), Denileukin diftitox (cutaneous T-cell lymphoma) lymphoma, CTCL), Immunocyanin (bladder and prostate cancer), MPS (Metallopanstimulin) (cancer), Aflibercept (non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), hormone-refractory metastatic prostate cancer, wet macular degeneration), Endostatin (cancer, rheumatoid arthritis, as well as inflammatory diseases such as Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis), Collagenase (debridement of chronic skin ulcers and severe burns, Dupuytren's contracture, Peyronie's disease), Human deoxyribonuclease I, dornase (Cystic fibrosis fibrosis; reduction of respiratory infections in selected patients with an FVC greater than 40% predicted), Hyaluronidase (used as an adjuvant to improve absorption and dispersion of injected drugs, especially in ophthalmic surgery and in certain contrast agents), Papain (for use in pressure ulcers, varicose and diabetic ulcers, burns, postoperative wounds, pilonidal cyst wounds), carbuncles of subcutaneous tissue, and other wounds), debridement of necrotic tissue or liquefaction of slough in acute and chronic lesions), L-Asparaginase (acute lymphoblastic leukemia, which requires exogenous asparagine for growth), Peg-asparaginase (acute lymphoblastic leukemia, which requires exogenous asparagine for growth), Rasburicase (pediatric patients with leukemia, lymphoma, and solid tumors undergoing anticancer treatment can develop tumor lysis syndrome), Human chorionic gonadotropin (HCG) (Assisted reproduction), Human follicle-stimulating hormone (HGF) (HGF), FSH (assisted reproduction), Lutropin-alpha (infertility with luteinizing hormone deficiency), Prolactin (hypoprolactinemia, serum prolactin deficiency, ovarian dysfunction in women, anxiety, arteriogenic erectile dysfunction in men, premature ejaculation, oligozoospermia, asthenospermia, seminal vesicles dysfunction, hypoandrogenism), alpha-1-proteinase inhibitor (congenital antitrypsin deficiency), Lactase (gas, bloating, cramps and diarrhea due to inability to digest lactose), Pancreatic enzymes enzymes) (lipase, amylase, protease) (cystic fibrosis, chronic pancreatitis, pancreatic insufficiency)insufficiency, post-Billroth II gastric bypass surgery, pancreatic duct obstruction, steatorrhoea, poor digestion, gas, bloating, adenosine deaminase (pegademase bovine, PEG-ADA) (severe combined immunodeficiency due to adenosine deaminase deficiency), abatacept (rheumatoid arthritis (especially when refractory to TNF-alpha inhibition)), alefacept (plaque psoriasis), anakinra (rheumatoid arthritis), etanercept (rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis) These may include, but are not limited to, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, ankylosing spondylitis), interleukin-1 (IL-1) receptor antagonists, Anakinra (inflammation and cartilage degeneration associated with rheumatoid arthritis), Thymulin (neurodegenerative diseases, rheumatism, anorexia nervosa), TNF-alpha antagonists (autoimmune diseases such as rheumatoid arthritis, ankylosing spinal cord inflammation, Crohn's disease, psoriasis, hidradenitis suppurativa, refractory asthma), Enfuvirtide (HIV-1 infection), and Thymosin alpha 1 (hepatitis B and C).
[0109] The length of the open reading frame (ORF) constituting the coding region (CR) is not limited, and the expression efficiency according to the length of the open reading frame (ORF) is not a major consideration in the development of the nucleic acid molecule according to the present disclosure, a recombinant expression vector using the same, and a nucleic acid vaccine for treatment or prevention. Codon usage can usually affect protein / peptide expression in various species, but codon usage bias in humans is known not to have a significant effect on protein / peptide expression, so it is not a consideration when developing a nucleic acid vaccine or gene therapy agent for humans. However, the initial codon should have a Kozak sequence (e.g., GCCACC), and the nucleotide sequence near the stop codon should also be optimized. If necessary, the third part of the codon sequence of the gene to be expressed in the coding region (CR) or its transcript, mRNA, can be changed to GC to increase the GC% of the target gene without changing the amino acid, thereby improving the stability of the mRNA.
[0110] In an alternative embodiment, the nucleic acid molecule may further include a nucleotide sequence that can increase the expression efficiency of the coding region (CR) linked in the form of an open reading frame (ORF). As an example, the nucleic acid molecule may have a transcription control element (TCCE) that promotes the transcription of the nucleic acid molecule adjacent to a translation control element, such as an upstream translation control element (U-TLCE). For example, the transcription control element (TCCE) may be located upstream of the upstream translation control element (U-TLCE). Such a transcription control element (TCCE) is not particularly limited, and will be described in detail in the section on recombinant expression vectors below to avoid duplication of explanation.
[0111] In addition, the nucleic acid molecule may contain a nucleotide sequence capable of inducing expression of an open reading frame (ORF) consisting of a gene constituting the coding region (CR) or its transcript sequence in addition to the above-mentioned translational regulatory element (TLCE), coding region (CR) and transcriptional regulatory element (TCCE). In one exemplary embodiment, a Kozak sequence may be inserted between the upstream translational regulatory element (U-TLCE) and the start codon of the coding region (CR).
[0112] In addition, a polyadenylation signal sequence and / or a polyadenosine sequence (PA) can be further inserted downstream of the coding region (CR), more specifically downstream of the second downstream translational regulatory element (D-TLCE2), which can further improve the translation efficiency of the open reading frame (ORF) consisting of a gene or its transcript sequence present in the coding region (CR) while stabilizing the dead nucleic acid molecule.
[0113] For example, when the nucleic acid molecule of the present disclosure consists of an RNA-form transcript sequence, the polyadenosine sequence (PA) can be a nucleotide sequence consisting of about 25 to about 400 adenosines, for example, 30 to 400, 50 to 250, or 60 to 250 adenosines.
[0114] In another exemplary embodiment, when the nucleic acid molecule of the present disclosure is composed of a nucleotide sequence in the form of DNA, a polyadenylation signal sequence (PA) can be located downstream of the second downstream translation control sequence (D-TLCE2). As an example, the polyadenylation signal sequence (PA) can be derived from SV40, human growth factor (hGH), bovine growth hormone (BGH), or rabbit beta-globin (rbGlob), but the present disclosure is not limited thereto.
[0115] Alternatively, the polyadenylation signal sequence or polyadenosine sequence (PA) can consist of a sequence in which a signal sequence such as 5'-GATCATCAGT-3' is inserted between two nucleotides consisting of a large number of adenosines, for example, 25 to approximately 400, 30 to 400, 50 to 250, or 60 to 250 adenosines, or their transcriptional sequence.
[0116] To insert a coding region (CR) into the nucleic acid molecule, the nucleic acid molecule may contain one or more cloning sites, preferably multiple cloning sites (MCS). The one or more cloning sites may contain one or more restriction endonuclease recognition sequences and / or sequences cleaved by restriction enzymes. Restriction enzymes may include natural restriction enzymes found in bacteria and archaea, as well as artificially produced restriction enzymes (e.g., zinc finger nucleases, restriction enzymes based on the DNA binding sites of TAL effectors, or DNA-based DNAznymes).
[0117] For example, naturally occurring restriction enzymes can be classified into 1) Type I restriction enzymes (which cleave at sites distant from the recognition site and require ATP, S-adenosyl-L-methionine, and magnesium ions), 2) Type II restriction enzymes (which cleave at specific sites within or slightly distant from the recognition site and mostly require magnesium ions), 3) Type III restriction enzymes (which cleave at sites slightly distant from the recognition site and require ATP but not ATP hydrolysis), 4) Type IV restriction enzymes (which target modification sites such as methylation, hydroxymethylation, or glucosyl-hydroxymethylation), and 5) Type V restriction enzymes (the cas9-gRNA complex of CRISPRs).
[0118] For example, the following restriction enzyme recognition sites and / or restriction enzyme cleavage sites (restriction enzymes) can be used: 5'-ATCGAT-3' (AngI), 5'-AGGCCT-3' (AatI), 5'-TGATCA-3' (AbaI), 5'-GGATCC-3' (BamHI), 5'-GCAGC(N)8-3' (BbvI), 5'-(N) 10 CGA(N)6TGC(N) 12 -3'(BcgI), 5'-(N)8GAG(N)5CTC(N) 13 -3'(BplI), 5'-GTCTC(N)-3'(BsmAI;Alw26I), 5'-ACTGGN-3'(BsrI), 5'-ATCGAT-3'(ClaI), 5'-CTCT TCN-3'(EarI), 5'-CTGAAG(N)16-3'(Eco57I), 5'-GAATTC-3'(EcoRI), 5'-CCWGG-3'(EcoRII; W is A or T ), 5'-GATATC-3' (EcoRV), 5'-GGATG(N)9-3' (FokI), 5'-GGCC-3' (HaeIII), 5'-AAGCTT-3' (HindIII) , 5'-CCGG-3'(HpaIII), 5'-GGTGA(N)8-3'(HphI), 5'-GGTACC-3'(KpnI), 5'-GATC-3'(MboI), 5'-ACGC GT-3'(MluI), 5'-GCCGGC-3'(NaeI), 5'-GATATG-3'(NdeII), 5'-GCCGGC-3'(NgoMIV), 5'-CATG-3'(N laIII), 5'-GCGGCCGC-3' (NotI), 5'-TTAATTAA-3' (PacI), 5'-CTGCAG-3' (PstI), 5'-GAGCTC-3' (SacI ), 5'-CCGCGG-3' (SacII), 5'-GTCGAC-3' (SalI), 5'-GCATC(N)5-3' (SfaNI), 5'-CCCGGG-3' (SmaI), 5'-TCGA-3' (TaqI), 5'-TCTAGA-3' (XbaI), 5'-CTCGAG-3' (XhoI), 5'-CGATCG-3' (PvuI) and combinations thereof.
[0119] In another exemplary embodiment, the cloning site may consist of SEQ ID NO:19.
[0120] The nucleic acid molecule may be DNA or RNA. According to an exemplary embodiment, the nucleic acid molecule according to the present disclosure may have an RNA form. If the nucleic acid molecule is in an RNA form, such as the coding region (CR) being composed of the transcript sequence of the open reading frame (ORF) encoding the above-mentioned protein or peptide, it is more advantageous than the nucleic acid molecule in a DNA form.
[0121] First, unlike DNA nucleic acid molecules, RNA nucleic acid molecules do not need to enter the nucleus of the host cell for transcription into mRNA due to their characteristics. Therefore, there is little potential risk of mutagenesis and they are quickly degraded in vivo, making them safe. RNA nucleic acid molecules have no possibility of entering the host chromosomes in the nucleus, antibiotic resistance genes, which are selection markers used for selective production in host cells, are not required to produce RNA nucleic acid molecules, and RNA has a shorter half-life than DNA, so it does not induce persistence genetic transformation. That is, general nucleic acid molecules are delivered into cells, activated for a short period of time, express target peptides / proteins, and are destroyed by enzymatic reactions within a few days, but the specific immune response to the initially expressed target peptides / proteins remains.
[0122] Secondly, the RNA-type nucleic acid molecule can induce a desired immune response in vivo even if used in a relatively small amount compared to the DNA-type nucleic acid molecule. As mentioned above, unlike the DNA-type nucleic acid molecule, the RNA-type nucleic acid molecule does not need to enter the nucleus, but only needs to pass through the cell membrane. Therefore, the RNA-type nucleic acid molecule can express the same level of target peptide even if used in a smaller amount than the DNA-type nucleic acid molecule.
[0123] Third, because all manufacturing processes can be artificially controlled, vaccines can be safely produced in small-scale GMP (good manufacturing practice) production facilities without the risk of biological contamination. RNA-based nucleic acid molecules only require small-scale GMP laboratory-level facilities and do not require direct handling of infectious agents (viruses or pathogenic microorganisms), allowing a variety of vaccines to be rapidly manufactured and produced.
[0124] Fourth, RNA-based nucleic acid molecules can induce stronger immune responses than naked DNA nucleic acid molecules. This is thought to be due to the cooperation between the innate immune response induced by the stem-loop structure of RNA nucleic acid molecules and the properties of RNA itself, and the adaptive immune response induced by the target peptide / protein expressed in immunized host cells. In addition, RNA nucleic acid molecules themselves produce complex antigens within cells, which can approach the MHC (major histocompatibility complex) class II of antigen-presenting cells and act as an ideal vaccine.
[0125] Fifth, RNA nucleic acid molecules are easier to produce than existing DNA nucleic acid molecules. As mentioned above, when producing RNA nucleic acid molecules, there is no need to directly handle the infectious agent. Instead, only the nucleic acid sequence of the neutralizing antibody induction-related part (neutralizing epitope) of the infectious agent to be expressed is artificially synthesized, and a large amount of RNA nucleic acid molecules can be produced only by in vitro transcription (IVT). Recently, reagents related to IVT reactions, especially DNA-dependent RNA polymerase, have been improved, and a large amount of RNA can be rapidly produced within 1 to 2 weeks using a small amount of DNA template. In addition, multiple antigens to induce an immune response can be simultaneously produced and mixed, and then immunized, and there is no special restriction on the gene length of the antigen to be expressed, so the applicability and convenience of producing NA nucleic acid molecules can be increased.
[0126] In another exemplary embodiment, the nucleic acid molecule may contain three or more downstream translational regulatory elements. Figure 2 is a schematic diagram showing the configuration of a nucleic acid molecule or polynucleotide that can efficiently express a gene of interest according to another exemplary embodiment of the present disclosure.
[0127] As shown in FIG. 2, the nucleic acid molecule includes a translational regulatory element (TLCE) including a nucleotide sequence having translation initiation activity, and a coding region (CR) operably linked to the translational regulatory element (TLCE) and consisting of an open reading frame (ORF) of a gene of interest (GOI), and may optionally include a transcriptional regulatory element (TCCE) and / or a polyadenylation signal sequence (PA) located upstream of the translational regulatory element (TLCE). The translational regulatory element (TLCE) includes an upstream translational regulatory element (U-TLCE) located upstream of the coding region (CR) and a downstream translational regulatory element (D-TLCE) located downstream of the coding region (CR). In this embodiment, the downstream translational regulatory element (D-TLCE) includes a first downstream translational regulatory element (D-TLCE1), a second downstream translational regulatory element (D-TLCE2) and a third downstream translational regulatory element (D-TLCE3) located sequentially between the coding region (CR) and the polyadenylation signal sequence (PA). The downstream translational regulatory element (D-TLCE) may be the same as the nucleic acid molecule of the first embodiment described with reference to FIG. 1, except that it includes a third downstream translational regulatory element (D-TLCE3).
[0128] As an example, the first downstream translational regulatory element (D-TLCE1), the second downstream translational regulatory element (D-TLCE2) and the third downstream translational regulatory element (D-TLCE3) may each independently comprise a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human troponin T1, slow backbone type (TNNT1), human albumin, human ferritin light chain (FTL), human CC motif chemokine ligand (CCL19), human vascular-associated migratory cell protein (AAMP), human ribosomal protein S27 (RPS27) and human defensin alpha 5 (DEFA5).
[0129] For example, the first downstream translational regulatory element (D-TLCE1), the second downstream translational regulatory element (D-TLCE2) and the third downstream translational regulatory element (D-TLCE3) may each independently comprise a translational regulatory element or a transcript sequence thereof selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
[0130] In exemplary embodiments, the first downstream translational regulatory element (D-TLCE1) may comprise a translational regulatory element derived from human TNNT1 or its transcript sequence, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from human DEFA5 or its transcript sequence, and the third downstream translational regulatory element (D-TLCE3) may comprise a translational regulatory element derived from human FTL or human RPS27 or its transcript sequence.
[0131] In other exemplary embodiments, the first downstream translational regulatory element (D-TLCE1) may comprise a translational regulatory element derived from human albumin or its transcript sequence, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from human DEFA5 or its transcript sequence, and the third downstream translational regulatory element (D-TLCE3) may comprise a translational regulatory element derived from human RPS27 or its transcript sequence.
[0132] In yet another exemplary embodiment, the first downstream translational regulatory element (D-TLCE1) may comprise a translational regulatory element derived from human RPS27 or a transcript sequence thereof, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from human FTL or a transcript sequence thereof, and the third downstream translational regulatory element (D-TLCE3) may comprise a translational regulatory element derived from any one selected from the group consisting of human CCL19, human RPS27 and human DEFA5 or a transcript sequence thereof.
[0133] In yet other exemplary embodiments, the first downstream translational regulatory element (D-TLCE1) may comprise a transcriptional translational regulatory element derived from human DEFA5 or its transcript sequence, the second downstream translational regulatory element (D-TLCE2) may comprise a translational regulatory element derived from human TNNT1 or its transcript sequence, and the third downstream translational regulatory element (D-TLCE3) may comprise a translational regulatory element derived from said human FTL or its transcript sequence.
[0134] Recombinant expression vectors, expression constructs The nucleic acid molecules shown in Figures 1 and 2, respectively, can be inserted into a recombinant expression vector. The recombinant expression vector includes a translational regulatory element (TLCE; e.g., U-TLCE and D-TLCE) having translation initiation activity, a coding region (CR), and may include a transcriptional regulatory element (TCCE) and / or a polyadenylation signal sequence (PA). That is, the recombinant expression vector may include a nucleic acid molecule described with reference to Figures 1 and 2, but this nucleic acid molecule may also be combined with other nucleic acids to encode a fusion protein or fusion peptide.
[0135] For example, vectors include viral vectors, DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors linked with CCAs (cationic condensing agents), DNA or RNA expression vectors encapsulated in liposomes, certain eukaryotic cells such as producer cells, and the like.
[0136] Exemplarily, the nucleic acid molecules of the present disclosure may be configured to enter and be expressed in mammalian cells. Such configurations are particularly useful for use in the treatment and / or prevention of infectious diseases. There are many ways to express a nucleic acid molecule in a host cell, and any suitable method can be used. For example, the nucleic acid molecules of the present disclosure can be inserted into a viral vector, such as an adenovirus, an adeno-associated virus, a retrovirus, a vaccinia or other pox virus. According to one exemplary embodiment, the nucleic acid molecules described above can be inserted into a suitable vector and then modified into an RNA form of the nucleic acid molecule through in vitro transcription (IVT).
[0137] Techniques for inserting nucleic acid molecules, e.g., DNA, into such vectors are already well known. Retroviral vectors can additionally contain targeting moieties, such as genes for selectable markers that facilitate identification or selection of transduced cells and / or genes encoding ligands that act as receptors for specific target cells. Targeting can also be performed by known methods using antibodies.
[0138] Numerous vectors are available and generally known in the art to which the disclosure pertains and can be used for the purposes of the present disclosure. The selection of an appropriate vector depends mainly on the size of the nucleic acid molecule to be inserted into the vector and the specific host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification or expression of heterologous polynucleotide, or both) and compatibility with the specific host cell in which the vector resides. The vector components generally include, but are not limited to, an origin of replication (especially if the vector is inserted into a prokaryotic cell), a selectable marker gene, a promoter, a ribosome binding site (RBS), a signal sequence, a heterologous nucleic acid insert, and / or a transcription termination sequence.
[0139] For example, an expression vector according to the present disclosure may include expression control elements, such as start codons, stop codons, polyadenylation signal sequences, enhancers, signal sequences for membrane targeting or secretion, that can affect the expression of proteins and / or peptides (e.g., reporter proteins / peptides, antigens, therapeutic proteins / peptides) encoded within the coding region (CR). Polyadenylation signal sequences (PA) increase the stability of the transcript or facilitate cytoplasmic transport. Enhancer sequences are nucleobase sequences located at various sites in a promoter that increase transcriptional activity compared to the transcriptional activity of the promoter in the absence of the enhancer sequence.
[0140] When the host is a bacterium of the genus Escherichia, the signal sequence may be a PhoA signal sequence, an OmpA signal sequence, etc., when the host is a bacterium of the genus Bacillus, the α-amylase signal sequence, a subtilisin signal sequence, etc. When the host is a yeast, the signal sequence may be an MF-α signal sequence, an SUC2 signal sequence, etc., when the host is an animal cell, the insulin signal sequence, an α-interferon signal sequence, an antibody molecule signal sequence, etc., but the present disclosure is not limited thereto.
[0141] One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a phage vector. Yet another type of vector is a viral vector into which additional DNA segments can be ligated into the viral genome. Some vectors (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors) are capable of autonomous replication in a host cell into which they are introduced. Other vectors (e.g., non-episomal mammalian vectors) may be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Some vectors are also capable of directing the expression of genes in the form of an open reading frame to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "recombinant vectors"). In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids.
[0142] In a specific embodiment of the present disclosure, the nucleic acid molecule can be inserted into the host cell using a viral expression system (vaccinia or other poxvirus, retrovirus or adenovirus). Exemplary viral vectors may include, but are not limited to, retroviral vectors derived from HIV, SIV, murine retroviruses, gibbon ape leukemia virus, AAVs (adeno-associated viruses) and adenoviruses, etc. (Miller et al., 1990, Mol. Cell Biol. 10:4239; J. Kolberg 1992, NIH Res. 4:43; Cornetta et al., 1991, Hum. Gene Ther. 2:215).Retroviral vectors derived from murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), ecotropic retroviruses, simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), etc. are widely used (Buchscher et al., 1992, J. Virol. 66(5):2731-2739; Johann et al., 1992, J. Virol. 66(5):1635-1640; Sommerfelt et al., 1990, Virol. 176:58-59; Wilson et al., 1989, J. Virol. 63:2374-2378; Miller et al., 1991, J. Virol. 65:2220-2224; Rosenberg et al., 1993, J. Virol. 65:2220-2224). and Fauci 1993 in Fundermental Immunology,Third Edition,WEPaul(ed.)Raven Press,Ltd.,New York and the references therein;Miller et al.,1990,Mol.Cell.Biol.10:4239;R.Kolberg 1992,J.NIH Res.4:43;Cornetta et al.,1991,Hum.Gene Ther.2:215).
[0143] The vector system according to the present disclosure can be constructed through various methods generally known in the technical field to which the present disclosure pertains, and specific methods therefor are disclosed in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001), which is incorporated herein by reference.
[0144] For example, the vector of the present disclosure can be typically constructed as a vector for cloning or a vector for expression. Also, the vector of the present disclosure can be constructed as a host in a prokaryotic cell or a eukaryotic cell. For example, the vector that can be used in the present disclosure can be produced by manipulating a plasmid (e.g., pSC101, ColE1, pBR322, pUC8 / 9, pHC79, pUC19, pET, etc.), a phage (e.g., λgt4λB, λ-Charon, λΔz1, λGEM.TM.-11, M13, etc.) or a virus (e.g., SV40, etc.) that is frequently used in the technical field to which the present disclosure belongs.
[0145] Constitutive or inducible promoters (e.g., transcriptional regulatory elements) can be used in the present disclosure, depending on the needs of a particular situation, which can be ascertained by one of ordinary skill in the art. Numerous promoters recognized by a variety of possible host cells are widely known. A selected promoter can be operably linked to a nucleic acid molecule having a coding region (CR) consisting of an open reading frame (ORF) of a gene or transcript encoding a peptide and / or protein by removing the promoter from the source nucleic acid molecule through restriction enzyme digestion and inserting the isolated promoter sequence into a selected vector. Both the native promoter sequence and many heterologous promoters can be used to direct the amplification and / or expression of the gene or transcript that constitutes the coding region (CR). However, heterologous promoters are preferred, as they generally allow greater transcription and higher yields of the expressed gene of interest compared to the native promoter.
[0146] For example, when the vector of the present disclosure is an expression vector and a prokaryotic cell is used as a host, it generally contains a transcriptional regulatory element (TCCE) such as a strong promoter (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, T7 promoter, etc.) that can drive transcription, a translational regulatory sequence (TLCE) for initiating translation, and a transcription / translation termination sequence. When E. coli is used as a host cell, the promoter and operator site of the E. coli tryptophan biosynthetic pathway (Yanofsky, C., J. Bacteriol., 158:1018-1024 (1984)) and the left-handed promoter of phage λ (pLλ promoter, Herskowitz, I. and Hagen, D., Ann. Rev. Genet., 14:399-445 (1980)) can be used as a regulatory site.
[0147] In addition, when the vector of the present disclosure is an expression vector and a eukaryotic cell is used as a host, a promoter derived from the genome of a mammalian cell (e.g., metallothionine promoter), a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, and HSV tk promoter), or a promoter derived from a bacteriophage (e.g., T7 promoter, T3 promoter, SM6 promoter) can be used, and generally has a polyadenylation signal sequence (PA) as a transcription termination sequence.
[0148] In addition, when the recombinant vector of the present disclosure is a replicable expression vector, it may contain a replication origin, which is a specific nucleic acid sequence from which replication is initiated. In addition, the recombinant vector may contain a selection marker. The selection marker is for selecting cells transformed with the vector, and a marker that confers a selectable phenotype, such as drug resistance, auxotrophy, resistance to cytotoxic agents, or expression of a surface protein, may be used. The vector of the present disclosure contains an antibiotic resistance gene commonly used in the art as a selection marker, for example, resistance genes against ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin, and tetracycline. Only cells expressing the selection marker survive in an environment treated with a selective agent, so that transformed cells can be selected. Representative examples of selection markers include auxotrophic markers such as ura4, leu1, and his3, but the above examples do not limit the types of selection markers that can be used in the present disclosure.
[0149] A variety of in vitro amplification techniques are known for amplifying sequences subcloned into expression vectors, including polymerase chain reaction (PCR), ligase chain reaction (LCR), Qβ-replicase amplification, and other RNA polymerase-based techniques (Sambrook et al., 1989, Molecular Cloning-A Laboratory Manual (2nd Ed) 1-3; US Patent No. 4,683,202; PCR protocols A Guide to Methods and Applications, Innis et al., eds. Academic Press Inc. San Diego, CA 1990. Improved methods of cloning in vitro amplified nucleic acids are described in US Patent No. 5,426,039).
[0150] The vector of the present disclosure can also be fused with other sequences to facilitate purification of recombinant proteins or peptides expressed therefrom. The sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA), and the most preferred is 6x His. Due to the additional sequence for purification, the protein expressed in the host can be quickly and easily purified through affinity chromatography. If necessary, a sequence encoding an Fc segment can also be fused to promote extracellular secretion of these recombinant proteins.
[0151] According to an exemplary embodiment of the present disclosure, the fusion protein expressed by the vector containing the fusion sequence is purified by affinity chromatography. For example, when glutathione-S-transferase is fused, glutathione, which is a substrate of this enzyme, can be used, and when 6x His is used, Ni-NTA His-binding resin column (Novagen, USA) can be used to quickly and easily obtain the desired recombinant protein.
[0152] The host cells capable of stably and continuously cloning and expressing the above-mentioned vectors may be any host cells well known in the art to which the present disclosure pertains, for example, Bacillus strains such as E. coli JM109, E. coli BL21(DE3), E. coli RR1, E. coli LE392, E. coli B, E. coli X1776, E. coli W3110, Bacillus subtilis, Bacillus thuringiensis, and Enterobacteriaceae and strains such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species. Furthermore, when the vector of the present disclosure is transformed into a eukaryotic cell, yeast (Saccharomyce cerevisiae), insect cells (e.g., SF9 cells) and human cells (e.g., CHO cell lines (Chinese hamster ovary), W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCK cell lines) can be used as host cells.
[0153] The vectors of the present disclosure can be used to genetically modify cells in vivo, ex vivo, or in vitro. There are various methods known for genetically modifying cells, including infecting or transducing cells with viral vectors, calcium phosphate precipitation, fusing recipient cells with bacterial protoplasts containing DNA, treating recipient cells with liposomes or microspheres containing DNA, endocytosis (DEAE dextran, receptor-mediated endocytosis), electroporation, micro-injection, etc.
[0154] For example, when the host cell is a prokaryotic cell, it can be performed by the CaCl2 method (Cohen, SNet al., Proc. Natl. Acac. Sci. USA, 9:2110-2114, 1973), the Hanahan method (Hanahan, D., J. Mol. Biol., 166:557-580, 1983) and / or the electroporation method (Dower, WJ et al., Nucleic. Acids Res., 16:6127-6145, 1988), etc. In addition, when the host cell is a eukaryotic cell, the vector can be injected into the host cell by microinjection (Capecchi, MR, Cell, 22:479, 1980)), calcium phosphate precipitation (Graham, FL et al., Virology, 52:456, 11973), electroporation (Neumann, E. et al., EMBO J., 1:841, 1982), liposome-mediated transformation (Wong, TK et al., Gene, 10:87, 1980), DEAE-dextran treatment (Gopal, Mol. Cell Biol., 5:1188-1190, 1985), and / or gene bombardment (Yang et al., Proc. Natl. Acad. Sci., 87:9568-9572, 1990), etc. The vector injected into the host cell can be expressed in the host cell, and in this case, a large amount of recombinant protein or recombinant peptide can be obtained. For example, if the expression vector contains a lac promoter, the host cell can be treated with IPTG to induce gene expression.
[0155] The above-mentioned nucleic acid molecules and / or expression constructs, which are expression systems into which the above-mentioned nucleic acid molecules are inserted as gene carriers, can be used as detection systems for detecting the presence or absence of a certain substance, vaccines for inducing an immune response, and / or therapeutic agents for treating a disease.
[0156] As an example, a pharmaceutical composition, such as a vaccine or therapeutic agent, comprising a pharma- ceutical effective amount of a nucleic acid molecule or an expression construct comprising a nucleic acid molecule may comprise a pharma- ceutical acceptable carrier, diluent and / or excipient. As used herein, a "pharma- ceutical effective amount" refers to an amount sufficient to achieve the efficacy or activity of the nucleic acid molecule according to the present disclosure.
[0157] In addition, such pharmaceutical compositions may contain a stabilizer, such as a cationic polymer, a cationic peptide, or a cationic polypeptide, capable of stabilizing the above-mentioned nucleic acid molecule or expression construct; at least one immune enhancing agent capable of enhancing an immune response; a sustained release formulation; and / or a lipid nano particle (LNP) capable of protecting the nucleic acid molecule, which is an active ingredient, and improving bioinjection activity.
[0158] The nucleic acid molecules or expression constructs of the disclosure can be administered by any suitable means, such as oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intradural and epidural and intranasal, and, if desired, means for localized therapeutic, intralesional administration. Parenteral injections include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration.
[0159] The nucleic acid molecules or expression constructs of the disclosure can be administered in any convenient dosage form, such as tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions can contain components conventional in pharmaceutical formulations, such as diluents, carriers, pH adjusters, sweeteners, bulking agents and additional active agents.
[0160] Hereinafter, the present disclosure will be described based on illustrative examples, but the present disclosure is not limited to the technical ideas described in the following examples.
[0161] Comparative Example 1: Preparation of a nucleic acid molecule containing an inserted Renilla luciferase (R / L) coding sequence A nucleic acid molecule was constructed into which the influenza virus hemagglutinin (HA) coding sequence was inserted. The template DNA sequence was designed as follows.
[0162] 5'-KpnI recognition sequence (GGTACC)-T7 promoter (SEQ ID NO:16)-upstream translational regulatory element from human troponin T1 (TNNT1) (SEQ ID NO:1)-PacI recognition sequence (TTAATTAA)-Kozak sequence (GCCACC)-Renilla luciferase coding sequence (R / L, SEQ ID NO:15)-ClaI recognition sequence (ATCGAT)-downstream translational regulatory element from human troponin T1 (human TNNT1) (SEQ ID NO:8)-EcoRI recognition sequence (GAATCC)-polyadenylation signal (SEQ ID NO:17)-restriction enzyme recognition sequence (SEQ ID NO:19).
[0163] The template DNA was inserted downstream of the pGH vector (SEQ ID NO: 18), cloned, linearized with a restriction enzyme, and subjected to in vitro transcription (IVT) to produce an RNA platform-type nucleic acid molecule (hereinafter referred to as "pHJ5L").
[0164] Example 1: Construction of a nucleic acid molecule containing an inserted Renilla luciferase (R / L) coding sequence The procedure of the comparative example was repeated, except that instead of the single TNNT1-derived translational regulatory element downstream of the coding region encoding Renilla luciferase, two downstream translational regulatory elements were inserted, each independently selected from the group consisting of SEQ ID NO:8 (derived from human TNNT1), SEQ ID NO:9 (derived from human albumin), SEQ ID NO:10 (derived from human FTL), SEQ ID NO:11 (derived from human CCL19), SEQ ID NO:12 (derived from human AAMP), SEQ ID NO:13 (derived from human RPS27) and SEQ ID NO:14 (derived from human DEFA5). Hereinafter, the downstream translation regulatory element of SEQ ID NO:8 will be abbreviated as "A", the downstream translation regulatory element of SEQ ID NO:9 will be abbreviated as "B", the downstream translation regulatory element of SEQ ID NO:10 will be abbreviated as "C", the downstream translation regulatory element of SEQ ID NO:11 will be abbreviated as "D", the downstream translation regulatory element of SEQ ID NO:12 will be abbreviated as "E", the downstream translation regulatory element of SEQ ID NO:13 will be abbreviated as "F", and the downstream translation regulatory element of SEQ ID NO:14 will be abbreviated as "G".
[0165] Experimental example 1: In vitro expression Mouse muscle cell line Nor10, human proliferative cell line HeLa, and human embryonic kidney cell line 293A were each plated in a 48-well plate at 8x10 4 The plates were then placed in a 37°C incubator to allow the cells to attach and grow for 24 hours. Each mRNA prepared in the Comparative Example and the Example was transfected at a concentration of 500 ng / well. Lipofection TM The 2000 samples were treated with OPTI-MEM medium for 1 μl per μg of each mRNA for 30 min or more to ensure sufficient mixing. TM After mixing with 2000, the 48-well plate with the cells attached was taken out, the supernatant was removed, and the plate was washed with PBS, after which it was further removed. 100 μl of medium was added on top, and mRNA and lipofection were performed. TM 100 μl of the 2000 mixture was added.
[0166] At this time, only 200 μl of medium was added to the negative control group. The plate was further placed in a 37°C incubator and removed at 6 and 24 hours to confirm expression. After 6 and 24 hours, the plate was removed, the supernatant was completely removed, and the plate was washed once with PBS. 80 μl of Renilla lysis buffer from the Renilla Luciferase Assay System Kit (Promega) was added on top to thoroughly destroy the cells, and the expression level of Renilla luciferase was measured by luminescence using a spectrophotometer as described in the kit. The expression level of Renilla luciferase after 6 hours in the Nor10 cell line to which the pHJ5L nucleic acid molecule prepared in the comparative example was applied was 2X10 7 After 24 hours, the expression level of Renilla luciferase was 2X10 6 It was.
[0167] The expression level of Renilla luciferase in the HeLa cell line after 6 hours of application of the pHJ5L nucleic acid molecule produced in the comparative example was 7x10 7 After 24 hours, the expression level of Renilla luciferase was 5.5X10 6 The expression level of Renilla luciferase in the 293A cell line to which the pHJ5L nucleic acid molecule prepared in the comparative example was applied after 6 hours was 4.3×10 7 After 24 hours, the expression level of Renilla luciferase was 2.2X10 6 It was.
[0168] The nucleic acid expression platform used as the base template was pHJ5L prepared in the Comparative Example, and the expression level of Renilla luciferase in this platform was set to 1. The expression level of Renilla luciferase in each RNA expression platform prepared in Example 1 was compared with that in pHJ5L. The measurement results are shown in Figures 3 to 8. As shown in Figures 3 to 8, the nucleic acid molecule prepared in the Example in which two downstream translation regulatory elements were inserted between the coding region and the 3' end efficiently improved the expression of Renilla luciferase inserted in the coding region in all of the Nor10 cell line, HeLa cell line, and 293A cell line.
[0169] Experimental Example 2: In vivo expression The mRNA prepared in Comparative Example and Example 1 was formulated with LNP (the same as that used in Moderna's vaccine) to prepare a composition for bioinjection. Mice were anesthetized through respiratory anesthesia and their ears were fixed. The compositions prepared in Comparative Example and Example with mRNA were injected into each mouse's ear at a concentration of 5 μg / 20 μl. Six and 24 hours after injection, mice were sacrificed, and the ears were cut and placed in 300 μl of Renilla dissolution buffer and cut into small pieces with scissors. The cut mouse ears were further crushed into small pieces using a homogenizer, and the supernatant was placed in 20 μl portions in a white 96-well plate. Then, luminescence was measured using a spectrophotometer using the Renilla substrate in the Renilla luciferase assay kit. The nucleic acid expression platform used as the base template was pHJ5L prepared in the Comparative Example, and the expression level of Renilla luciferase in this platform was set to 1. The expression level of Renilla luciferase in each RNA expression platform prepared in the Examples was compared with that in pHJ5L. The measurement results are shown in Figures 9 and 10. As shown in Figures 9 and 10, the expression level of Renilla luciferase was increased from the nucleic acid molecule in which two downstream translation regulatory elements were inserted between the coding region and the 3' end.
[0170] Example 2: Construction of a nucleic acid molecule containing an inserted Renilla luciferase (R / L) coding sequence The procedure of Example 1 was repeated, except that instead of inserting two downstream translational regulatory elements downstream of the coding region encoding Renilla luciferase, three downstream translational regulatory elements were inserted, each of which was independently the same downstream translational regulatory element as used in Example 1.
[0171] Experimental example 3: In vitro expression The nucleic acid molecule prepared in Example 2 was transformed into a human embryonic kidney cell line, 293A cell line, in the same manner as in Experimental Example 1, and the expression level of Renilla luciferase was measured by luminescence using a spectrophotometer. The nucleic acid expression platform used as the base template was pHJ5L prepared in the Comparative Example, and the expression level of Renilla luciferase in this platform was set to 1, and the expression level of Renilla luciferase in each RNA expression platform prepared in Example 2 was compared with that in pHJ5L. The measurement results are shown in Figures 11 and 12. As shown in Figures 11 and 12, the nucleic acid molecule prepared in the Example in which three downstream translation regulatory elements were inserted between the coding region and the 3' end efficiently improved the expression of Renilla luciferase inserted into the coding region in the 293A cell line.
[0172] Although the present disclosure has been described above based on exemplary embodiments and examples of the present disclosure, the present disclosure is not limited to the technical ideas described in the above embodiments and examples. Rather, a person having ordinary knowledge in the technical field to which the present disclosure belongs can easily consider various modifications and changes based on the above embodiments and examples. However, it is clear from the appended claims that all such modifications and changes are within the scope of the present disclosure.
Claims
1. A translational regulatory element; a coding region operably linked to said translational regulatory element, The translational regulatory elements include an upstream translational regulatory element located upstream of the coding region and a downstream translational regulatory element located downstream of the coding region; The downstream translational regulatory element is a nucleic acid molecule comprising a plurality of downstream translational regulatory elements.
2. The nucleic acid molecule of claim 1 , wherein the downstream translational regulatory element comprises a first downstream translational regulatory element and a second downstream translational regulatory element located downstream of the coding region.
3. The nucleic acid molecule of claim 1, wherein the multiple downstream translation regulatory elements each comprise a translation regulatory element derived from any one of genes selected from the group consisting of human troponin T1, slow backbone type (human TNNT1), human albumin, human ferritin light chain (human FTL), human C-C motif chemokine ligand (human CCL19), human vascular-associated migratory cell protein (human AAMP), human ribosomal protein S27 (human RPS27) and human defensin alpha 5 (human DEFA5), or a transcript sequence thereof.
4. The nucleic acid molecule of claim 1, wherein the multiple downstream translational regulatory elements each independently comprise a translational regulatory element selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, or a transcript sequence thereof.
5. The first downstream translational regulatory element comprises a translational regulatory element derived from human TNNT1 or a transcript sequence thereof; The nucleic acid molecule of claim 2, wherein the second downstream translational regulatory element comprises a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human albumin, human FTL, human CCL19, human AAMP, human RPS27 and human DEFA5.
6. the first downstream translational regulatory element comprises a translational regulatory element derived from human albumin or a transcript sequence thereof; The nucleic acid molecule of claim 2 , wherein the second downstream translational regulatory element comprises a translational regulatory element derived from human DEFA5 or a transcript sequence thereof.
7. The nucleic acid molecule of claim 2, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from the human FTL or its transcript sequence, and the second downstream translational regulatory element comprises a translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, human RPS27 and human DEFA5 or its transcript sequence.
8. The nucleic acid molecule of claim 2, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from human CCL19 or a transcript sequence thereof, and the second downstream translational regulatory element comprises a translational regulatory element derived from any one selected from the group consisting of human TNNT1, human FTL, human CCL19, human RPS27 and human DEFA5 or a transcript sequence thereof.
9. The nucleic acid molecule of claim 2, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from the human AAMP or a transcript sequence thereof, and the second downstream translational regulatory element comprises a translational regulatory element derived from any one selected from the group consisting of human albumin, human FTL, human RPS27 and human DEFA5 or a transcript sequence thereof.
10. The nucleic acid molecule of claim 2, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from human RPS27 or a transcript sequence thereof, and the second downstream translational regulatory element comprises a translational regulatory element derived from any one selected from the group consisting of human TNNT1, human albumin, human FTL, human CCL19, human AAMP, human RPS27 and human DEFA5 or a transcript sequence thereof.
11. The nucleic acid molecule of claim 2, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from human DEFA5 or a transcript sequence thereof, and the second downstream translational regulatory element comprises a translational regulatory element derived from any one selected from the group consisting of human TNNT1, human albumin, human FTL, human CCL19, human AAMP and human RPS27 or a transcript sequence thereof.
12. The nucleic acid molecule of claim 2 , wherein the downstream translational regulatory element further comprises a third downstream translational regulatory element located downstream of the second downstream translational regulatory element.
13. The nucleic acid molecule of claim 12, wherein the third downstream translational regulatory element comprises a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human troponin T1, slow backbone type (TNNT1), human albumin, human ferritin light chain (FTL), human C-C motif chemokine ligand (CCL19), human vascular-associated migratory cell protein (AAMP), human ribosomal protein S27 (RPS27) and human defensin alpha 5 (DEFA5).
14. The nucleic acid molecule of claim 12, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from human TNNT1 or a transcript sequence thereof, the second downstream translational regulatory element comprises a translational regulatory element derived from human DEFA5 or a transcript sequence thereof, and the third downstream translational regulatory element comprises a translational regulatory element derived from human FTL or human RPS27 or a transcript sequence thereof.
15. The nucleic acid molecule of claim 12, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from human albumin or a transcript sequence thereof, the second downstream translational regulatory element comprises a translational regulatory element derived from human DEFA5 or a transcript sequence thereof, and the third downstream translational regulatory element comprises a translational regulatory element derived from human RPS27 or a transcript sequence thereof.
16. The nucleic acid molecule of claim 12, wherein the first downstream translational regulatory element comprises a translational regulatory element derived from human RPS27 or a transcript sequence thereof, the second downstream translational regulatory element comprises a translational regulatory element derived from human FTL or a transcript sequence thereof, and the third downstream translational regulatory element comprises a translational regulatory element derived from any one selected from the group consisting of human CCL19, human RPS27 and human DEFA5 or a transcript sequence thereof.
17. The nucleic acid molecule of claim 12, wherein the first downstream translational regulatory element comprises a transcriptional translational regulatory element derived from human DEFA5 or a transcript sequence thereof, the second downstream translational regulatory element comprises a translational regulatory element derived from human TNNT1 or a transcript sequence thereof, and the third downstream translational regulatory element comprises a translational regulatory element derived from human FTL or a transcript sequence thereof.
18. The nucleic acid molecule of claim 1, wherein the upstream translational regulatory element comprises a translational regulatory element or a transcript sequence thereof derived from any one selected from the group consisting of human troponin T1, slow backbone type (human TNNT1), human albumin, human ferritin light chain (human FTL), human C-C motif chemokine ligand (human CCL19), human vascular-associated migratory cell protein (human AAMP), human ribosomal protein S27 (human RPS27) and human defensin alpha 5 (human DEFA5).
19. The nucleic acid molecule of claim 1, wherein the upstream translational regulatory element comprises a translational regulatory element selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, or a transcript sequence thereof.
20. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is RNA.
21. The nucleic acid molecule of claim 1 , further comprising a transcriptional regulatory element operably linked to the coding region.
22. The nucleic acid molecule of claim 1 , further comprising a polyadenylation signal sequence or a polyadenosine sequence located downstream of the downstream translational regulatory sequence.
23. 2. The nucleic acid molecule of claim 1, wherein the coding region encodes at least one of a reporter protein or a fragment thereof and a marker or selection protein or a fragment thereof.
24. The nucleic acid molecule of claim 1 , wherein the coding region encodes an antigen or a fragment thereof.
25. 25. The nucleic acid molecule of claim 24, wherein the antigen comprises a peptide that is a pathogen antigen, a tumor antigen, or a variant or derivative thereof.
26. The nucleic acid molecule of claim 1 , wherein the coding region encodes a peptide or a fragment thereof for the treatment of a disease.
27. A recombinant expression vector having the nucleic acid molecule of claim 1 inserted therein.
28. A method for producing a protein or peptide by injecting a nucleic acid molecule described in claim 1 or a recombinant expression vector into which the nucleic acid molecule described in claim 1 has been inserted into a living body and expressing a protein or peptide from the injected nucleic acid molecule.
Citation Information
Patent Citations
Modifications of RNA that Confer Transcript Stability and Transcriptional Efficiency
JP2009509516A
Artificial nucleic acid molecules containing 5'TOPUTR
JP2015517803A
